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Not many but much – ‘Non multa sed multum’ – is the motto chosen in 1991 by Serafino 
Zappacosta and the other founders of the EFIS-EJI Advanced School of Immunology 
Ruggero Ceppellini. The motto was pertinent to the 29th Course of the School, where the 
participants enjoyed excellent lectures on the state-of-the-art of the meta-organism, that is 
the hybrid ecosystem made of our cells and microbes. Health and disease, including 
cancer, are properties of the meta-organism, and so are responses to new immunotherapies 
of cancer.  
 
The Course was directed by Francesco Colucci (University of Cambridge, UK), Ennio 
Carbone (University of Magna Graecia, Catanzaro, Italy), Giorgio Trinchieri (National 
Institute of Health, USA), Laurence Zitvogel (Gustave Rouissy Cancer Campus, Paris, 
France) and Guido Kroemer (Centre de Recherche Des Cordeliers, Université Paris 
Descartes, Paris, France). The 25 attendants from 7 different countries and the 12 lecturers 
gathered at the Former Swedish Solar Observatory and now conference centre of the Italian 
National Research Centre (CNR) – Osservatorio Cultura Ricerca Formazione Divulgazione 
(Figure 1, 2), in the stunning surroundings of Anacapri, Capri Island, Italy – made available 
thanks to CNR members, Francesca Di Rosa (Institute of Molecular Biology and Pathology, 
CNR, Rome, Italy) and the President of the School Silvia Fontana Zappacosta (CNR, 
Naples, Italy). Nine of the participants received travel fellowships (Figure 3) made available 
by the European Federation of Immunological Society (EFIS), the European Academy of 
Tumor Immunology (EATI), and the Department of Experimental and Clinical Medicine of the 
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Magna Graecia University of Catanzaro, Italy. Fluidigm Corporation and Miltenyi Biotech 
sponsored the event. The introductory lecture was given by Ennio Carbone who talked 
about the historical background, the structure and the activities of the School (1). 
 
 
Figure 1. The Osservatorio Cultura Ricerca          Figure 2. Introduction to the course: Laurence Zitvogel (left),  
Formazione Divulgazione of the Italian National        Giorgio Trinchieri (Centre) and Guido Kroemer (right) introducing  
Research Centre (CNR)            the course. On the background are the contact details of the 
EFIS Advanced School of Immunology Ruggero Ceppellini – founded          
by Serafino Zappacosta in 1991 – and its motto in Latin: “Non multa 
sed multum”.  
 
The theme of the 29th Course was “Microbes, Immunity and Cancer” and it was an idea of 
Giorgio Trinchieri, who in the 1970’s trained with the great Ruggero Ceppellini himself in 
Turin and Basel. In his lecture on the origin of innate immunity as mediator of the crosstalk 
between microbes and host, Giorgio Trinchieri took the attendants on a fantastic journey 
from the primordial eukaryotic cells to modern innate immunity. Innate immunity evolved 
more than 2 billion years ago from the symbiosis of unicellular organisms with their 
microbes, which then became mitochondria. Diverse examples of symbiosis were offered, 
from unicellular organisms to deep-sea anglerfish (also known as sea-devil), to the Hawaiian 
bobtail squid and its glowing bacteria.  All multicellular organisms live in symbiosis with 
microbes and in fact our bodies are meta-organisms harbouring about 100-fold more 
microbial DNA than human DNA. We respond to external stimuli, and so do our 
commensals, which, unlike us, can actually change their DNA through generations of 
offspring and under selective pressures, which adds to the complexity and flexibility of the 
meta-organism. Major roles have now been established for the microbiome in physiology, 
including in regulating metabolism, behaviour, and cognition, as well as in disease. Cancer, 
for example, is a disease of the meta-organism. Because innate immune cells do not 
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distinguish between commensals and pathogens, we ought to think that microbe-
associated molecular patterns (MAMPs) – rather than pathogen-associated molecular 
patterns (PAMPs) – are the molecular mediators of the cross talk between microbes and 
host. Various experimental models were discussed, including the recent approach of using 
laboratory mice born to wild mice, which have natural microbiota and can model human 
immune responses (2).   
 
Laurence Zitvogel gave a thought-provoking lecture titled “The concept of Immunogenic 
Cell Death in oncology”. She pointed out that successful radio-, chemo- and even targeted-
therapy may all in fact be immuno-therapies, because they induce immunogenic cell death 
(ICD). These therapies indeed stress cancer cells which, by dying of ICD, in turn, alert 
immune cells, particularly dendritic cells, which recognise stress through DAMPs (damage- 
or danger-associated molecular patterns) using their pattern recognition receptors (PRR). 
Indeed, distressed or altered self-antigens may be more important than neo-antigens on 
tumour cells to alert the immune system. The gut microbiota affects responses to 
chemotherapy and certain specific commensal bacteria provide adjuvants, and in so doing 
they turn immunological tolerance into immunogenicity (3). 
  
Guido Kroemer gave an inspiring lecture on the importance of healthy nutrition, caloric 
restriction and autophagy for healthy ageing. For example, mice with deficiencies in the 
autophagy pathway become much more obese and even diabetic when put on high caloric 
intake though either fat diet or sugary drinks, with bad consequences on aging, cancer and 
cardiovascular diseases. Some micronutrients, for example spermidine delays aging in 
humans (4) and is produced by the microbiome and also found in some foods, including 
aged cheese, soybeans, peas, nuts, broccoli, mushrooms, pears and apples. Spermidine 
also reduces aging in yeast, nematode, flies, and mice. Kroemer explored the interactions 
between, on the one hand, responses to cancer therapies mediated by the immune system 
and, on the other, increased life span induced by autophagy, which can be triggered 
pharmacologically, genetically or through nutrition. The link between better responses to 
cancer therapies and improved life span is provided by ‘caloric restriction mimetics’ (CRM) 
and ICD inducers. Indeed, fasting, or CRM associated with ICD improves the outcome of 
cancer therapies in mice. His lab and collaborators are now applying a high throughput 
platform to identify new CRMs. The evidence that the microbiome influences 
immunotherapies of cancer was also reviewed. New research into mouse models of the 
genetically determined premature aging progeroid syndrome (Huntchinson Gilford) was 
shared, showing that progeroid mice lack the microbe Akkermansia muciniphila, which 
induces autophagy and is increased in healthy centenarians. In conclusion autophagy was 
put at the core of onco-metabolism, immuno-metabolism and whole-body metabolism, 
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including its microbiome, because autophagy ‘dilates’ time by increasing longevity, 
improving health and helping to treat cancer (5-8). 
 
Junior faculty member Oliver Kepp, from the Kroemer lab, gave a detailed account of how 
cellular stress ignites anticancer responses and concentrated on the mechanisms and the 
clinical relevance of ICD. He also presented ways to couple a systems biology platform that 
screens compounds to ignite ICD with pre-clinical mouse models of immunotherapy using 
those compounds (9)   
 
Junior Faculty member Lisa Derosa from the Zitvogel lab discussed how gut dysbiosis 
compromises the efficacy of immunotherapy in patients and in mice. She also discussed the 
emerging concept of oncomicrobiome and how this is a new opportunity in both research 
and to improve patient care. The challenge, which will require an extensive multi-disciplinary 
approach, is to identify a minimalist ecosystem that governs responses to the cancer 
immunotherapies.  
 
Nicola Segata (University of Trento, Italy) gave an inspiring lecture titled “Shotgun 
metagenomics for high-resolution investigations of the human microbiome”, where 
metagenomics is intended as the study of the total collection of uncultured microorganisms 
in an environment using high throughput sequencing. There are about 1M more microbes in 
and on us than there are people on our planet. It is clear, for example, that the gut 
microbiome is linked to several diseases, including liver cirrhosis, inflammatory bowel 
disease, obesity, type 2 diabetes and colorectal cancer. How the infant microbiome is 
acquired was also discussed. The gut microbiome is partially inherited at birth. There can 
also be vertical transmission of microbial genetic material from mother to child, but only for 
some sub-types of germs, as illustrated with E. coli phylotypes. Transmitted strains are also 
more stable.  However, some of the microbiome is still unknown, for example about 40% of 
the skin microbial genetic material – dubbed “the dark matter” of our microbiome. Could 
this unknown microbial genetic material be the missing link between microbes and 
diseases? For what it can be seen in the known 60%, any two unrelated people share only 
about 35% of their microbiome, suggesting that the human microbiome is highly variable, 
unique and personal, and also largely uncharacterized. There may be thousands of 
unknown species and millions of unsampled genes. Elegant work was presented showing 
how to expand our horizon by large scale metagenomics across westernised and non-
westernised populations, and by comparing modern and ancient humans (10, 11). 
 
Petter Brodin (Karolinska Institute, Stockholm, Sweden) gave a fantastic lecture titled 
“System-level analysis of immune-microbiome interactions early in life”. He made a strong 
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case for new technology now being available to enable us to study the human immune 
system as a system and over time, thus avoiding the reductionistic approach of studying 
one’s favourite cell type at a given, fixed time. A critical time seems to be early in life, when 
the immune system develops also through exposure to the microbiome. Following the 
development of the immune system in newborns, his team has found a stabilisation of gut 
microbiome-immune system relationship at a specific time window early in life, which is 
reminiscent of the ‘weaning reaction to the gut microbiome’ in mice, and that may well be 
linked to the development of several conditions, including inflammatory bowel disease, 
asthma and various other allergies (12-14). Within the Human Protein Atlas Project, Petter 
Brodin also presented the new initiative “The Human Blood Atlas”, which contains single 
cell type information on genome-wide RNA expression profiles of human protein-coding 
genes covering 18 cell types of B and T cells, NK cells, monocytes, granulocytes and 
dendritic cells isolated with cell sorting followed by RNA-seq analysis. In addition, the 
Human Blood Atlas also contains an analysis of the protein secreted and found in human 
blood and compared to various tissues. 
(https://www.proteinatlas.org/humanproteome/blood) 
 
Jolanda De Vries (Radboud University, Nijmegen, The Netherlands) gave an impressive 
lecture and presented unpublished results from the multiple clinical trials conducted in her 
centre using dendritic cell vaccines for patients with cancer (15).  
 
Sebastian Kobold (Ludwig-Maximilians University, Munich, Germany) made a strong case 
for the need of progress in new cancer treatments, and in particular for T-cell therapies of 
solid tumours. He guided the attendants through the fascinating journey of the 
development of T-cell-based immunotherapies, culminating in the FDA-approved anti-
CD19 CAR T cells immunotherapy for B-cell lymphoma in 2017. He also analysed the 
adverse effects and toxicity of CAR T cell-therapies and assessed the current state-of-the-
art in treatments of solid tumours, including sarcomas, glioblastoma and pancreatic ductal 
adenocarcinoma. Despite many ongoing clinical trials, there are three major barriers to 
success: lack of T-cell entry into tumours, insufficient tumour cell recognition and local 
immunosuppression. New experimental approaches aimed at trespassing these barriers 
were discussed (16). 
 
Junior Faculty member Costanza Maria Cristiani from Ennio Carbone’s lab summarised 
new research on NK cells and cancer. She reviewed the evidence that NK cells recognize 
target cells in a complementary way to cytotoxic T cells and that they are particularly 
effective against cancer stem cells. In addition, NK cells can provide biomarkers to assist 
cancer immunotherapies, particularly for solid tumours (17).  




Junior Faculty member Amiran Dsutzev, from the Trinchieri lab, discussed microbes and 
cancer. He provided evidence for how the genetic background can affect composition of 
gut microbiota and that it is mostly, but not exclusively, the innate immune system that 
impacts on the composition of the gut microbiota. For example, a deficiency in Myd88, 
Il17 or Ifng predisposes mice to dysbiosis and development of colon cancer. The 
dysbiosis induced by Myd88 deficiency in CD11b+ cells is caused by loss of Reg3g 
production in colonic epithelial cells, resulting in E.coli outgrowth (18).   
 
Junior Faculty member Marie Vétizou, also from the Trinchieri lab, discussed how dietary 
fibers affect responses to immune checkpoint blockers. She revised the evidence from both 
mouse and clinical studies that supports an important role for the gut microbiome 
composition in the modulation of responses to immune-checkpoint inhibition in cancer 
therapy. She also discussed recent progress like the importance of discovering 
microbiome-related biomarkers to predict patient responses across clinical centers. 
Moreover, fecal transfer from responder patients or healthy donors to non-responder 
patients could be implemented, if a favourable microbiome were to be identified. Other 
important issues are the characterization of both the mechanisms that make the 
microbiome enhance cancer therapy, and the perturbations that induce or maintain a 
favorable microbiome composition (19). 
 
The informal atmosphere throughout the whole course facilitated discussions at the poster 




Figure 3. The 9 recipients of the Travel Fellowships 
 
      Figure 4. The Faculty and the participant 
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